Clinical trials initiated for novel immunotherapy combo for ovarian cancer
April 7, 2016Medical Communications, Research and Development MedImmune, cancer research institute, clinical trial, ludwig, ovarian cancer, ventirx
A cross collaboration between industry and not-for-profit organisations will see Ludwig Cancer Research and the Cancer Research Institute partner with …
Incyte buys rights to Eli Lilly’s Ruxolitinib; shares jump
April 7, 2016Research and Development, Sales and Marketing Eli Lilly, Incyte, Licencing, M&A, MA, Novartis
Shares in Incyte Corp (Nasdaq: INCY) soared to close up over 11.5% Wednesday as the company said it has purchased …
UK’s first commercial synthetic biology foundry begins production
April 7, 2016Manufacturing and Production, Research and Development Biological, biologics, foundry, synbicite
SynbiCITE’s has begun production at the UK’s first commercial synthetic biology foundry. The site provides automated end-to-end design, construction and …
Shire reassures Baxalta acquisition on track in the aftermath of Pfizer-Allergan breakup
April 7, 2016Business Services, Sales and Marketing AbbVie, Allergan, Baxalta, Deals, Financial, Merger & Acquisition, Pfizer, Shire
Ireland-headquartered Shire Plc (LSE: SHP) has reassured its $32-billion merger deal with US-based Baxlata (NYSE: BXLT) remains on track in …
Allergan to partner with Heptares in Alzheimer’s disease collaboration
April 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Alzheimer's, Heptares, R&D, collaboration, commercialisation, h1, h4, neurological disorders, partnership, research and development, treatments
Bouncing back quickly from the collapse of the collapse of the Pfizer inversion deal, Allergan (NYSE:AGN) has announced a new …
Novartis receives EU approval for blood disorder treatment in children
April 7, 2016Research and Development, Sales and Marketing EMA, EU, ITP, Novartis, Revolade, approval, blood disorder, children, chronic itp
Novartis (NYSE: NVS) has announced that Revolade (eltrombopag) has been approved in the EU for use in paediatric patients aged …
5 things to know about the Pfizer/Allergan inversion collapse
April 6, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 5, 5 things, Allergan, Pfizer, collapse, inversion, reasons
The end came very quickly for the Pfizer/Allergan $160 billion deal once the US Treasury Department announced a new set …
Tesaro shares rise as J&J buys rights to prostate cancer drug for $85 million
April 6, 2016Business Services, Research and Development, Sales and Marketing Cancer, J&J, JJ, M&A, MA, Tesaro, drug, licence agreement, research
Shares in oncology-focussed Tesaro Inc (Nasdaq: TSRO) jumped Wednesday after the company said pharma major Johnson & Johnson (NYSE: JNJ) …
Sepha embarks on a busy Spring of International Exhibitions
April 6, 2016Medical Communications sepha, spring
Pharmaceutical packaging specialist, Sepha Ltd, has sprung into the spring quarter with a number of international exhibitions. Having developed a …
Allergan, Pfizer confirm termination of $160 billion merger
April 6, 2016Business Services, Research and Development, Sales and Marketing
Botox maker Allergan Plc (NYSE:AGN) and US pharma giant Pfizer (NYSE: PFE) on Wednesday confirmed they have terminated the merger …
Sun to cut jobs in Irish facility closure; Lilly announce further investment in the country
April 6, 2016Manufacturing and Production, Research and Development Eli Lilly, Ireland, Kinsale, Sun Pharma, cashel, investment, lilly
There was mixed news for pharmaceutical manufacturing in Ireland as Sun Pharma announced its decision to close its facility based …
Celltrion’s biosimilar for J&J’s arthritis drug gets UF FDA okay
April 6, 2016Manufacturing and Production, Research and Development
Korea-based Celltrion (Kosdaq: 068270) has received US regulatory approval for its biosimilar version of the arthritis drug marketed by Johnson …
Pfizer to call off $160 billion merger with Allergan
April 6, 2016Business Services, Research and Development, Sales and Marketing Allergan, Pfizer, deal, legal, merger and acquisition, regulation
US pharma giant Pfizer Inc (NYSE: PFE) has decided to terminate the $160 billion merger with Botox-maker Allergan Plc (NYSE: …
Phase III trial initiated in Merck and Pfizer partnership for renal cell carcinoma drug
April 6, 2016Research and Development Merck, Pfizer, avelumab, carcinoma, inlyta, javelin, partnership, phase III, renal
The first patient has been treated in the Phase III clinical trial, which sees Merck (ETR: MRK) and Pfizer (NYSE: …
Merck receives CE Mark approval for new liquid biopsy test for colorectal cancer
April 6, 2016Medical Communications, Research and Development, Sales and Marketing CE Mark, Merck, biomarker, biopsy, colorectal cancer, liquid biopsy, ras, sysmex inostics
Merck (ETR: MRK) has announced that their new liquid biopsy RAS biomarker test for metastatic colorectal cancer, developed in collaboration …
EMVO appoints new general manager
April 5, 2016Medical Communications andreas walter, emvo
The European Medicines Verification Organisation (EMVO), the body established to implement the European Falsified Medicines Directive and the Delegated Regulation, …
Valeant’s ad hoc committee closes chapter on Philidor controversy
April 5, 2016Medical Communications, Research and Development, Sales and Marketing Philidor, Valeant, ad hoc, ad hoc committee
Valeant (NYSE: VRX) has announced that the ad hoc committee of the board of directors has finished its review of …
Pfizer’s tofacitinib shows promise for psoriatic arthritis treatment in Phase III trial
April 5, 2016Medical Communications, Research and Development, Sales and Marketing Allergan, Pfizer, Xeljanz, merger, phase III, psoriatic arthritis, tofacitinib
Pfizer has announced positive top-line results from their latest Phase III study investigating Xeljanz (tofacitinib citrate). The OPAL Broaden trial …
Samsung Bioepis takes AbbVie to court over attempts to delay Humira biosimilars
April 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Biogen, Humira, Samsung Bioepis, biosimilars, rheumatoid arthritis
Samsung Bioepis has filed a lawsuit against Abbvie (NYSE: ABBV) to stop the maker of the world’s bestselling drug Humira …
Flexion Therapeutics announce results for Zilretta trials in osteoarthritis pain
April 5, 2016Manufacturing and Production, Research and Development drugs, flexion, flexion therapeutics, osteoarthritis, pipeline, treatments, zilretta
Flexion Therapeutics has presented positive results from two pivotal clinical trials for its lead drug candidate, Zilretta, which show that …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
